Zeleciment rostudirsen (z-rostudirsen)

Name: Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Natural history, survival, and mortality
Published: 2026-09-14T15:39:06-04:00

Duchenne muscular dystrophy

Also known as DYNE-251

Manufacturer: Dyne Therapeutics
Regulatory submission: BLA submitted May 2026
Launch: Anticipated in the first quarter of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Natural history, survival, and mortality

2 evidence topics · 3 sources

Genotype and loss of ambulation in corticosteroid-treated patients

“earlier age at LoA for the exon 51 skip amenable cohort (p < .001) when compared with the rest of the cohort.” (opens the source at this quote in a new tab)

Survival in more recent birth cohorts

“patients born after 1990 have a median life expectancy of 28.1 years (95% CI 25.1, 30.3).” (opens the source at this quote in a new tab)